News Snapshot:
language (Yicai Global) Aug. 5 -- Less than half a month after its product Azvudine, China’s first domestic oral medication for Covid-19, was approved to be on the market, Genuine Biotech submitted a listing application to the Hong Kong Exchanges and Clearing. But the firm did reveal how much money it will raise. The company will use the funds raised to produce and commercialize the drug and do clinical research on therapies for the human immunodeficiency virus, the hand-foot-mouth disease, and neoplastic hematologic disorders, Genuine Biotech said in the application. The firm has two subsidiaries – Henan Genuine Biotech formed...
